Study on anti-fibrosis treatment decisions in pulmonary fibrosis
Part of Lungs & breathing clinical trials.
This study looks at how patients with pulmonary fibrosis (lung scarring) make decisions about stopping or continuing anti-fibrosis medications, especially if they have had side effects. It may help doctors and patients understand the best treatment choices.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have pulmonary fibrosis (including idiopathic pulmonary fibrosis or progressive pulmonary fibrosis).
- You are 18 years or older.
- You are receiving outpatient care and were referred by your doctor.
- You have taken or are currently taking pirfenidone, nintedanib, or nerandomilast.
- You have had at least one side effect from these medications.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how people with pulmonary fibrosis feel emotionally and socially while taking antifibrotic medications like nintedanib or pirfenidone. It aims to understand the real-world impact of these treatments on daily life.
This study uses safe, painless scans (like muscle ultrasound and a body composition test) to track changes in muscle and fat in patients with IPF or PPF who are starting anti-fibrotic medication. The goal is to better understand how these treatments affect your body.
This study looks at factors that shape how people with pulmonary fibrosis experience the clinical study process (and possibly care). It may help improve future studies and support for patients by understanding what helps or gets in the way.
This study continues treatment for people who already completed a previous study with an Avalyn inhaled antifibrotic drug. It aims to check the long-term safety of the medication for patients with certain types of lung scarring.
This trial tests whether combining two medications—nerandomilast (a new anti-inflammatory drug) and mycophenolate (an immunosuppressant you may already be taking)—can safely slow lung scarring in people with pulmonary fibrosis other than IPF. The goal is to help doctors decide if this combination is right for you.
This study tests whether a new tablet called SYH2059 can help slow lung scarring in adults with idiopathic pulmonary fibrosis (IPF), a condition where lung tissue becomes thick and stiff over time. You'll take the study drug alongside your current lung treatment to see if it improves your breathing and lung function.
Hear when a new Pulmonary Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.